Advertisement

Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification

  • Elena Jansen
  • Christina Hamisch
  • Daniel Ruess
  • Dieter Henrik Heiland
  • Roland Goldbrunner
  • Maximilian I. Ruge
  • Oliver Schnell
  • Stefan J. GrauEmail author
Clinical Study

Abstract

Purpose

To provide detailed long-term data after initial observation for patients after histological confirmation of low grade (WHO II) gliomas according to molecular stratification.

Methods

A series of 110 patients with watchful waiting strategy after initial surgery for LGG and re-surgery at tumor progression were analyzed. Progression-free survival, time to malignant transformation, post-recurrence survival, and overall survival were estimated with the Kaplan–Meier method. Prognostic factors were identified by the Log Rank test and Cox multivariate proportional hazards model.

Results

The cohort comprised 18 IDH wild type (IDHwt) and 53 IDH mutated (IDHmut) astrocytomas, and 39 IDH mutated and 1p 19q co-deleted (IDHmut/codel) patients. The median follow-up was 126 (95% CI 109–143) months. Surgery was gross total resection in 58, subtotal resection in 28, and biopsy in 24 patients. Progression-free survival rates at 5, 10 and 15 years was 38% 18% and 1%. The corresponding malignant transformation rates were 17%, 39% and 71%.

The initial extent of resection influenced progression-free survival, time to malignant transformation and overall survival. Molecular subtype IDHmut/codel was the strongest prognostic factor for overall survival and for time to malignant transformation.

Conclusion

The strongest determinant of the patients’ course after initial watchful waiting was the molecular tumor status. Extensive resection may increase time to progression and malignant transformation. Observation may be justified in selected patients.

Keywords

Low grade glioma IDH mutation Observation 1p19q co-deletion 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

This is a retrospective study with no study-related procedures involving human participants. The study was approved by the local ethical committees (approval numbers 16-443 (cologne) and 100020/09 (Freiburg)) and is in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Buckner JC, Shaw EG, Pugh SL et al (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344–1355.  https://doi.org/10.1056/NEJMoa1500925 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301.  https://doi.org/10.1200/JCO.1997.15.4.1294 CrossRefPubMedGoogle Scholar
  3. 3.
    Chaichana KL, McGirt MJ, Laterra J et al (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112:10–17.  https://doi.org/10.3171/2008.10.JNS08608 CrossRefPubMedGoogle Scholar
  4. 4.
    Schmidt MH, Berger MS, Lamborn KR et al (2003) Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 98:1165–1169.  https://doi.org/10.3171/jns.2003.98.6.1165 CrossRefPubMedGoogle Scholar
  5. 5.
    Soffietti R, Baumert BG, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133.  https://doi.org/10.1111/j.1468-1331.2010.03151.x CrossRefPubMedGoogle Scholar
  6. 6.
    Sanai N, Chang S, Berger MS (2011) Low-grade gliomas in adults. J Neurosurg 115:948–965.  https://doi.org/10.3171/2011.7.JNS101238 CrossRefPubMedGoogle Scholar
  7. 7.
    Schiff D, Brown PD, Giannini C (2007) Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366–1373.  https://doi.org/10.1212/01.wnl.0000277271.47601.a1 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Coburger J, Merkel A, Scherer M et al (2016) Low-grade glioma surgery in intraoperative magnetic resonance imaging. Neurosurgery 78:775–786.  https://doi.org/10.1227/NEU.0000000000001081 CrossRefPubMedGoogle Scholar
  9. 9.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820.  https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
  10. 10.
    Youland RS, Kreofsky CR, Schomas DA et al (2017) The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. J Neurooncol 135:535–543.  https://doi.org/10.1007/s11060-017-2599-1 CrossRefPubMedGoogle Scholar
  11. 11.
    Shaw EG, Wang M, Coons SW et al (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065–3070.  https://doi.org/10.1200/JCO.2011.35.8598 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Johnson BE, Mazor T, Hong C et al (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343(80):189–193.  https://doi.org/10.1126/science.1239947 CrossRefPubMedGoogle Scholar
  13. 13.
    Murphy ES, Leyrer CM, Parsons M et al (2018) Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol Phys 100:965–971.  https://doi.org/10.1016/j.ijrobp.2017.12.258 CrossRefPubMedGoogle Scholar
  14. 14.
    Hunter C, Smith R, Cahill DP et al (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987–3991.  https://doi.org/10.1158/0008-5472.CAN-06-0127 CrossRefPubMedGoogle Scholar
  15. 15.
    Weller M, van den Bent M, Tonn JC et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329.  https://doi.org/10.1016/S1470-2045(17)30194-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Grau SJ, Hampl JA, Kohl A-C et al (2017) Impact of resection on survival of isocitrate dehydrogenase 1-mutated world health organization grade II astrocytoma after malignant progression. World Neurosurg 103:180–185.  https://doi.org/10.1016/j.wneu.2017.03.123 CrossRefPubMedGoogle Scholar
  17. 17.
    Jakola AS, Myrmel KS, Kloster R et al (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308:1881–1888.  https://doi.org/10.1001/jama.2012.12807 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350.  https://doi.org/10.1200/JCO.2012.43.2229 CrossRefPubMedGoogle Scholar
  19. 19.
    van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990.  https://doi.org/10.1016/S0140-6736(05)67070-5 CrossRefPubMedGoogle Scholar
  20. 20.
    Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343.  https://doi.org/10.1200/JCO.2012.43.2674 CrossRefPubMedGoogle Scholar
  21. 21.
    Smith JS, Chang EF, Lamborn KR et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–1345.  https://doi.org/10.1200/JCO.2007.13.9337 CrossRefPubMedGoogle Scholar
  22. 22.
    Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–766.  https://doi.org/10.1227/01.neu.0000318159.21731.cf CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Capelle L, Fontaine D, Mandonnet E et al (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 118:1157–1168.  https://doi.org/10.3171/2013.1.JNS121 CrossRefPubMedGoogle Scholar
  24. 24.
    Majchrzak K, Kaspera W, Bobek-Billewicz B et al (2012) The assessment of prognostic factors in surgical treatment of low-grade gliomas: a prospective study. Clin Neurol Neurosurg 114:1135–1144.  https://doi.org/10.1016/j.clineuro.2012.02.054 CrossRefPubMedGoogle Scholar
  25. 25.
    Kreth FW, Faist M, Grau S, Ostertag CB (2006) Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer 106:1372–1381.  https://doi.org/10.1002/cncr.21750 CrossRefPubMedGoogle Scholar
  26. 26.
    Tom MC, Varra V, Leyrer CM et al (2019) Risk factors for progression among low-grade gliomas after gross total resection and initial observation in the molecular era. Int J Radiat Oncol 104:1099–1105.  https://doi.org/10.1016/j.ijrobp.2019.04.010 CrossRefGoogle Scholar
  27. 27.
    Shaw EG, Berkey B, Coons SW et al (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835–841.  https://doi.org/10.3171/JNS/2008/109/11/0835 CrossRefPubMedGoogle Scholar
  28. 28.
    Lin AL, White M, Miller-Thomas MM et al (2016) Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol 130:529–533.  https://doi.org/10.1007/s11060-016-2247-1 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498.  https://doi.org/10.1056/NEJMoa1402121 CrossRefGoogle Scholar
  30. 30.
    Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693.  https://doi.org/10.1007/s00401-015-1409-0 CrossRefPubMedGoogle Scholar
  31. 31.
    Jung T-Y, Jung S, Moon J-H et al (2011) Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 113:752–757.  https://doi.org/10.1016/j.clineuro.2011.08.002 CrossRefPubMedGoogle Scholar
  32. 32.
    Baumert BG, Hegi ME, van den Bent MJ et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521–1532.  https://doi.org/10.1016/S1470-2045(16)30313-8 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Aibaidula A, Chan AK-Y, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337.  https://doi.org/10.1093/neuonc/nox078 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Prosthetic DentistryUniversity Hospital of CologneCologneGermany
  2. 2.Department of General Neurosurgery, Center for NeurosurgeryUniversity Hospital CologneCologneGermany
  3. 3.Department of Neurosurgery, Medical Center University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany
  4. 4.Department of Stereotaxy and Functional Neurosurgery, Center for NeurosurgeryUniversity Hospital CologneCologneGermany

Personalised recommendations